Clinical trials: Factor XIII Deficiency
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects
This trial is conducted in Europe. The aim of this clinical trial is to compare the metabolism of a blood-clotting drug (recombinant Factor XIII)) produced by two different manufacturers (Novo Nordisk and Avecia) in healthy male…
- Conditions
- Congenital Bleeding Disorder, Congenital FXIII Deficiency, Healthy
- Trial name
- NCT01082406
- Testing
- catridecacog, recombinant factor XIII
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
This trial will be conducted in Asia, Europe and the United States of America (USA). The aim of this clinical trial is to investigate long-term safety of rFXIII when administered for prevention of bleeding episodes in children…
- Trial name
- mentor™5 (NCT01253811)
- Testing
- catridecacog
- Where
- 4 sites in United States, Israel and 1 more
- Volunteers
- 6 people
- Sponsor
- Novo Nordisk A/S
Brain Tumor, Vascular Lesion
Factor XIII and Pulmonary Embolism in Neurosurgical Patients
Two studies (Gerlach et al. 2000; Gerlach et al. 2002) described the impact of factor XIII on the risk of prospective hemorrhage for patients undergoing craniotomy.
- Conditions
- Brain Tumor, Vascular Lesion, Factor XIII Deficiency, Pulmonary Embolism
- Trial name
- NCT01106937
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency
This trial is conducted in Europe and United States of America (USA). The aim of this clinical trial is to investigate the pharmacokinetics (at which rate the substance is distributed and eliminated from the body) and the safety…
- Trial name
- mentor™4 (NCT01230021)
- Testing
- catridecacog
- Where
- 10 sites in United States, Israel and 1 more
- Volunteers
- 6 people
- Sponsor
- Novo Nordisk A/S
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
This trial was conducted in the United States of America (USA). The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in patients with…
- Trial name
- NCT00056589
- Testing
- catridecacog
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Novo Nordisk A/S
Factor XIII Deficiency
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Congenital deficiency of factor XIII is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII.
- Trial name
- NCT00945906
- Testing
- FXIII Concentrate (Human) (FXIII)
- Where
- 25 sites in United States
- Volunteers
- 61 people
- Sponsor
- CSL Behring
Factor XIII Deficiency, ST-Elevation Myocardial Infarction
Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
In medical practice, a combination of clinical exam, electrocardiograms, circulating biomarkers, and imaging is used to gain insights on the prognosis after myocardial infarction.
- Conditions
- Factor XIII Deficiency, ST-Elevation Myocardial Infarction, Myocardial Haemorrhage, Coronary Microvascular Disease
- Trial name
- eXIST (NCT03523624)
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- University of Padova
Impaired Wound Healing, Factor XIII Deficiency
Wound Healing Abnormalities in Major Abdominal Surgery
This clinical observational study investigates the incidence of wound healing abnormalities in patients undergoing major abdominal surgery.
- Trial name
- INWOUND (NCT00735579)
- Where
- Germany
- Volunteers
- 260 people
- Sponsor
- Klinikum St. Georg gGmbH
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the safety of monthly replacement therapy of recombinant factor XIII in patients with congenital FXIII deficiency.
- Trial name
- mentor™2 (NCT00978380)
- Testing
- catridecacog
- Where
- 34 sites in United States, Austria and 10 more
- Volunteers
- 63 people
- Sponsor
- Novo Nordisk A/S
Postpartum Hemorrhage, Coagulation Disorder
SWIFT - SWIss Factor XIII Trial in PPH
The goal of this trial is to determine if postpartum blood loss can be reduced by replenishing coagulation factor XIII (FXIII) at an early stage of postpartum hemorrhage (PPH).
- Conditions
- Postpartum Hemorrhage, Coagulation Disorder, Coagulation Factor Deficiency, Hemorrhage
- Trial name
- SWIFT (NCT06481995)
- Testing
- Fibrogammin
- Where
- 9 sites in Switzerland
- Volunteers
- 988 people
- Sponsor
- Christian Haslinger
Acquired Factor XIII Deficiency Disease
Impact of Acquired FXIII Deficiency on Morbidity and Mortality
Observational prospective study aiming to assess acquired FXIII deficiency implications in morbidity and mortality
- Trial name
- NCT04416594
- Testing
- Data collection
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Patricia Duque González
Burns, Coagulation Disorder
Factor XIII in Major Burns Coagulation
Prospective observational study in which FXIII levels and coagulation tests and cicatrization are measured during the 30 days after the thermal trauma.
- Conditions
- Burns, Coagulation Disorder, Factor XIII Deficiency, Cicatrization
- Trial name
- NCT03188913
- Testing
- Coagulation tests
- Volunteers
- 20 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Factor XIII Deficiency
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Congenital deficiency of factor XIII (FXIII) is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII.
- Trial name
- NCT00885742
- Testing
- FXIII Concentrate (Human)
- Where
- 23 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- CSL Behring
Hemophilia, Factor XIII Deficiency
Clinical Trial of Factor XIII (FXIII) Concentrate
Congenital deficiency of Factor XIII is a rare but potentially life threatening disorder. It is inherited in an autosomal recessive fashion.
- Trial name
- NCT00640289
- Testing
- Fibrogammin P
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Children's Hospital of Orange County
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers
This trial was conducted in Europe. The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in healthy volunteers.
- Conditions
- Congenital Bleeding Disorder, Congenital FXIII Deficiency, Healthy
- Trial name
- NCT01847989
- Testing
- catridecacog
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
The trial is conducted in Europe, North America and Asia. The aim of this trial is to evaluate catridecacog (recombinant factor XIII (rFXIII)) treatment in patients with inherited FXIII deficiency.
- Trial name
- NCT00713648
- Testing
- catridecacog
- Where
- 35 sites in United States, Austria and 9 more
- Volunteers
- 41 people
- Sponsor
- Novo Nordisk A/S
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers
This trial was conducted in Europe. The aim of this trial was to investigate safety and pharmacokinetics of multiple doses of catridecacog (recombinant factor XIII, rFXIII) in healthy volunteers.
- Conditions
- Congenital Bleeding Disorder, Congenital FXIII Deficiency, Healthy
- Trial name
- NCT01848002
- Testing
- catridecacog
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Multiple Trauma, Coagulation Disorder
Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma
Coagulation factor XIII (FXIII), a plasma transglutaminase, is known as the final enzyme of the coagulation cascade, responsible for a cross-linking of fibrin to strengthen blood clot.
- Conditions
- Multiple Trauma, Coagulation Disorder, Coagulation Factor Deficiency, Coagulation Defect; Acquired
- Trial name
- NCT03634215
- Testing
- fibrinogen plasma concentration, coagulation factor XIII activity
- Where
- 3 sites in Czechia
- Volunteers
- 357 people
- Sponsor
- Masaryk Hospital Krajská zdravotní a.s.
Factor XIII Deficiency
A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding.
- Trial name
- NCT00883090
- Testing
- FXIII Concentrate (Human)
- Where
- 6 sites in United States, Spain
- Volunteers
- 15 people
- Sponsor
- CSL Behring